Rubicon Research, a General Atlantic-promoted pharma company, is all set to launch its Rs 1,377.5-crore initial public offering (IPO) on October 9, joining the wave of major public issues next week alongside Tata Capital’s Rs 15,512-crore IPO and LG Electronics India’s Rs 11,607-crore offering.

The anchor book for the IPO will open for a single day on October 8, while public subscription will remain open until October 13. Rubicon plans to issue fresh shares worth Rs 500 crore, with General Atlantic Singapore offloading shares worth Rs 877.5 crore via the offer-for-sale route.

Promoters currently hold 77.97 per cent of the company, while the public owns 22.03 per cent, including Shivanand Mankekar HUF (14.42 per cent) and Amansa Investments (3.3 per cent). In recent months, General Atlant

See Full Page